SMARCAL1 and Schimke immuno-osseous dysplasia: In five (24%) children (patients No 2, 4, 8, 17, and one child without any pathogenic variants in SMARCAL1) without evident SIOD features, we tried treatment with the cacineurin inhibitors cyclosporine A or tacrolimus before molecular genetic tests were performed.